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Inhalation therapy for equine lower respiratory disease 
R. Scott Pirie and Bruce C. McGorum 
Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, 
Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG 
 
Introduction 
The delivery of drugs to horses via the inhalation route is an increasingly adopted therapeutic 
approach in equine practice, predominantly aimed at the treatment of equine lower airway 
disease, including, but not restricted to, both severe and mild to moderate equine asthma 
(previously termed Recurrent Airway Obstruction [RAO] and Inflammatory Airway Disease 
[IAD], respectively) and Exercise Induced Pulmonary Haemorrhage. Like many therapeutic 
approaches, there are both advantages and disadvantages associated with inhalation therapy 
which must be considered when selecting the most appropriate treatment on a case-by-case 
basis. Additionally, there are a number of unanswered questions with respect to inhalation 
therapy in the horse, most notably in relation to the efficiency and variability of drug delivery 
to the lower airways which, considering the specific equine airway diseases in which inhalation 
therapy is commonly applied, constitutes the principal target site (i.e. small and terminal 
airways) of drug deposition. Even in the absence of lower airway disease, achieving such drug 
deposition within a system designed to avoid particle penetration of the lungs can be 
challenging. This review provides an overview of the principals of inhalation therapy, the 
advantages and disadvantages of this approach, the techniques commonly used to administer 
inhaled medication and the drugs commonly administered via the inhaled route. 
 
General principles of inhalation therapy 
Inhalation therapy describes the delivery of drug directly to the airways, a process which relies 
on the generation of an aerosol containing microdroplets of medication, either generated from 
a liquid reservoir or consisting of dry powder. Atomisation of liquids is generally achieved by 
jet, ultrasonic or mesh nebulisation or by the use of a pre-calibrated metered dose inhaler 
device. Each method of liquid atomisation differs with respect to the properties of the aerosol 
generated (i.e. particle size distribution).  
 
For the purpose of this article, the target site will be regarded as the lower airways, bearing in 
mind that, in certain rarer circumstances, the aim of inhalation therapy may be to maximise 
drug deposition more proximally in the respiratory tract (e.g. nasal cavity or trachea). The 
particle size distribution of the generated aerosol constitutes a major determinant of the 
likelihood of the aerosolised drug reaching the lower airways; however other factors also play 
a role in determining the efficiency of this delivery (summarised in Table 1). It should be 
emphasised that the aerosol particle size distribution considered optimal for drug delivery to 
the equine smaller airways is largely based on human patient derived data. The American 
Conference of Governmental Industrial Hygienists (ACGIH) generally assumes the 
aerodynamic diameter of aerosolised particles within the respirable fraction (defined as the 
aerodynamic diameter at which 50% penetration of that fraction occurs) to be 4 micrometres. 
Although the likelihood of significant differences between the size-dependent penetration of 
particles into the equine and human lung has been proposed (Ivester et al, 2014), in the absence 
of experimental data to define equine-specific particle fractions, it is generally assumed that 
particles less than 4-5 micrometres are likely to reach the lower airways in the horse (Hoffman, 
1997; Lavoie, 2001). Larger particles will deposit in the larger airways via a process of inertial 
impaction and particles less than 0.5 micrometres will likely be expired within the exhaled 
breath (Duvivier et al 1997).  
 
A number of factors influence the particle size distribution of the generated aerosol. These 
include factors associated with the method of aerosol generation (e.g. air flow rates during jet 
nebulisation) and factors inherent to the aerosolised solution (e.g. density, viscosity, surface 
tension and hygroscopic growth potential; Table 1) (Duvivier et al 1997). Other particle 
dependent determinants of lower airway deposition include electrostatic charge and particle 
shape. Therefore, the assumption that all aerosolised drugs are likely to share the same 
distribution properties is false and data are very much lacking on the aerosol distribution 
properties of many medications which are increasingly administered by the inhalation route in 
equine practice. Variations in properties such as viscosity will directly influence the particle 
size distribution and factors such as tonicity (e.g. hypotonicity) may indirectly influence lower 
airway deposition via the induction of a protective bronchoconstrictive response (Table 1). 
Most medications intended for inhaled administration are isotonic, a potentially important 
factor when considering the administration of other drug formulations (e.g. drugs formulated 
for intravenous use) via the inhalation route. Furthermore, such formulations may also contain 
other components (e.g. preservatives) which result in bronchoconstriction, thus further 
compromising their deposition within the smaller airways. For example, human studies 
evaluating the use of inhaled tobramycin (with and without phenol preservatives), aztreonam 
and colistin confirmed the induction of significant and acute, yet transient, bronchoconstriction 
following inhalation (Hodson et al, 2002; Nikolaizik et al, 2002; Retsch-Bogart et al 2008). 
Such effects were attributed to osmolality and preservatives within some of the solutions and 
recommendations were made to routinely administer bronchodilators before dosing.  
In addition to particle dependent factors, a number of patient dependent factors influence lower 
airway deposition (Table 1). It has been proposed that the horse constitutes a highly appropriate 
subject for inhalation therapy due to its high inspiratory flow rates and the prolonged drug 
retention times which result from the relatively low breathing frequency. However, for dry 
powder inhalation at least, excessively high flow rates have been shown to promote impaction 
in the upper airways with lower flow rates enhancing sedimentation and therefore more distal 
deposition of the aerosol (Timsina et al 1994). Furthermore, compliance with the technique of 
administration will vary greatly between individuals, with some horses becoming agitated and 
increasing their breathing frequency and others adopting prolonged periods of breath-holding. 
Indeed, it may be deemed dangerous to persist with inhalation therapy in some horses which 
become distressed during the administration procedure. This disparity in breathing pattern will 
inevitably contribute significantly to the variation in drug deposition between both patients and 
treatment episodes. Unfortunately, the standard technique employed in human inhalation 
therapy, consisting of a slow inhalation followed by a period of breath holding, cannot be 
applied to horses due to the voluntary nature of this manoeuvre. 
 
Adequate ventilation of the diseased lung is a necessary requirement for successful inhalation 
therapy and any detected or anticipated compromise in ventilation should be considered prior 
to embarking on this mode of drug delivery (Table 1). For example, a case of severe equine 
asthma with significant lower airway obstruction (e.g. bronchospasm, mucus plugging) is 
unlikely to benefit from the delivery of drugs via the inhalation route, at least until the 
obstruction is partially relieved via other therapeutic approaches. In such cases, the degree of 
lower airway obstruction will be reflected in the altered breathing pattern of the horse; most 
evidently, an exaggerated abdominal effort during expiration. Similarly, areas of consolidated 
lung resulting from bacterial pneumonia will almost certainly not benefit from the delivery of 
antibiotics via the inhalation route. 
 
What are the advantages and disadvantages of inhalation therapy? 
The main advantage of inhalation therapy is the delivery of drug to the intended site of action; 
namely, the airway. Although drug delivery to the airways can readily be achieved by systemic 
administration, this approach results in widespread exposure of extra-pulmonary organs to the 
administered drug, with the potential for the induction of unwanted adverse effects. For 
example, the systemic administration of beta adrenergic agonist drugs, intended to relieve 
bronchospasm, has been associated with tachycardia, excitement and excessive sweating. 
Other examples include the reduction in gastrointestinal motility associated with the systemic 
administration of anticholinergic drugs and adrenal suppression and immunosuppression 
associated with the frequent systemic administration of corticosteroids. Inhaled administration 
of drug, directly to the targeted site of action, also has the potential to reduce drug costs, 
although this must be offset against the costs associated with the equipment required to 
administer the drug via this route. Additionally, inhaled therapy has the potential to shorten the 
drug withdrawal time required prior to competition in performance animals and in accordance 
with regulations regarding tissue residues, although specific data are very much lacking in this 
respect. Finally, the direct delivery of drug to the intended site of action results in a more rapid 
onset of action. 
 
One principle disadvantage of inhalation therapy is the vast array of factors which influence 
the particle size distribution of the generated aerosol, including the properties of the aerosolised 
solution and the method of aerosol generation. When considered along with the variable 
breathing strategies of the horse, these factors render it almost impossible to accurately predict 
the efficiency of drug deposition within the equine lower airways. In addition to these predicted 
variations, the authors have also demonstrated marked variation in both total and respirable 
drug (salbutamol) deposition within a standardised in vitro experimental model following both 
MDI and mesh nebuliser-generated aerosol delivery via a commercially available equine spacer 
device (R.S. Pirie personal communication). This work demonstrated an additional source of 
variation in drug delivery which could not be attributed to differences in drug composition, 
method of aerosol generation or breathing strategy, as a constant (non-tidal) airflow was 
maintained throughout the duration of delivery. A similar degree of variation in output has also 
been reported by Votion et al (1997) in relation to both ultrasonic nebulisation and jet aerosol 
delivery and by Janssens et al (1999) in relation to MDI delivery to children, with the 
magnitude of variation in the latter study being dependent on the spacer used. 
 
Consequently, and in comparison to systemic therapy, it is difficult to develop definitively 
appropriate dosing strategies. Therefore, there is a general consensus that the drug should be 
administered largely to effect in each case, with the published recommendations being used as 
guidelines. Similarly, the certain variation in drug delivery, and therefore systemic absorption, 
between cases renders any attempt to develop reliable and reproducible drug withdrawal 
recommendations problematic.  
 
In comparison to enteral or parenteral drug administration, inhalation therapy is time 
consuming and often necessitates several daily administrations. Furthermore, a degree of 
exposure of the handler and administrator to the active drug is inevitable and performing the 
technique in a well ventilated environment is advisable. 
 Available techniques for equine inhalation therapy  
A variety of inhalation therapy delivery systems are available for use in the horse, some of 
which are custom made for equine use and some are adapted from equivalent human systems.  
 
Mechanical nebulisation 
Mechanical nebulisers have been used for many years to generate aerosols for equine inhalation 
therapy. Aerosols are generated either by applying airflow to draw liquid from a reservoir 
through a capillary tube (jet nebulisation), by vibration of a standing reservoir of liquid 
(ultrasonic nebulisation) or more recently by forcing the liquid through multiple apertures in a 
vibrating mesh (mesh nebulisation).  
 
Jet nebulisation: For jet nebulisation, gas flows are usually generated using either a compressor 
(generally designed for human inhalation therapy) or a compressed gas cylinder with an 
appropriate regulator. As the diameter of aerosolised particles is inversely proportional to 
airflow, difficulty in generating sufficiently high flow rates constitutes the principal limitation 
of jet nebulisation, whereby a minimal air flow of 6-8L/min at the input of the jet nebuliser is 
required to generate an aerosol with a high particle content less than 5 micrometres in diameter 
(Clay et al 1983a and b). Furthermore, the equipment required for jet nebulisation can be 
cumbersome and expensive and the delivery of drug can be prolonged, a significant 
consideration when the procedure, which necessitates connection to either a mains electricity 
supply or compressed gas cylinder, requires continued restraint of the horse.  
 
Ultrasonic nebulisation: Ultrasonic nebulisation has also been used in equine inhalation 
therapy for a number of years whereby the aerosol is generated by vibrations of a piezo-electric 
crystal driven by an alternating electric field. Despite the relative ease with which ultrasonic 
nebulisation can be applied in the field, it is generally accepted that ultrasonic nebulisation 
generates a wider variation in aerosolised particle sizes compared with jet nebulisation. 
 
Mesh nebulisation: Recent developments in nebuliser technologies have resulted in the 
development of mesh nebulisers and an equine-specific system (Flexineb®, Nortev Ltd, 
Galway, Ireland; Figure 1) is currently in common use in equine practice. Mesh systems are 
silent and can be battery powered, both significant advantages in relation to equine inhalation 
therapy.  The particle size distribution within the aerosol is largely determined by the size of 
the apertures within the vibrating mesh and the authors recently measured the mass median 
aerodynamic diameter (MMAD) of aerosolised salbutamol particles generated by the 
Flexineb® system to be 1.4 micrometres, with a geometric standard deviation of 3.2 
micrometres and therefore consistent with the size distribution required to penetrate the equine 
lower airways (R.S. Pirie personal communication).  
 
Metered dose inhalers (MDIs) 
MDIs are a popular alternative to mechanical nebulisers, permitting the relatively rapid 
administration of an aerosol with less variation in particle size. Previous studies have 
demonstrated superior deposition of MDI particles in the equine lung versus standard 
nebulisation. Furthermore, the non-requirement for electrical power constitutes an additional 
advantage of this method of administration. With MDIs, the active drug is either suspended or 
dissolved in a volatile propellant which is released through a metering valve with each manual 
actuation of the device. In human inhalation therapy, due to the rapid propulsion of the aerosol, 
these devices require coordination between inhalation and actuation of the device to ensure 
effective drug delivery. The importance of adopting an optimal technique for MDI use has been 
emphasised in relation to both human and equine inhalation therapy, with a view to maximising 
the efficiency of drug delivery to the lower airways and any deviation from optimal technique 
is considered to adversely affect drug output (Table 1). In human medicine, correct MDI 
technique has generally been assessed through adherence to 7 key sequential steps; namely, 
shaking the MDI and removing the cap, exhaling prior to MDI use, holding the MDI upright, 
proper timing of actuation, slow inspiratory effort, one MDI actuation per breath, breath 
holding for ≥5 seconds. Much of the advice offered to horse owning clients has understandably 
been adapted from these steps, although some cannot be applied to the horse (e.g. slow 
inspiratory effort and breath holding). A recent study (in press) by the authors has critically 
appraised some of the recommendations often provided on the optimal use of an MDI device. 
With respect to the efficiency of salbutamol delivery, this study failed to demonstrate any 
significant detrimental effect of not shaking the MDI prior to each of multiple consecutive 
actuations (provided the device was shaken prior to the first actuation), not maintaining an 
optimal angle of MDI actuation within the spacer and performing multiple rapid actuations in 
rapid succession, all factors which could significantly impact on the level of compliance of the 
user. 
 
Dry powder inhalers 
Dry powder inhalers are breath-actuated devices which rely on the inspiratory airflow of the 
patient to de-aggregate the dry powder drug. Unlike the MDI, the dry powder system permits 
optimal coordination between inspiration and drug delivery. However, the necessity for the 
generation of high inspiratory flow rates, which can be achieved voluntarily in many human 
patients, requires the use of a mask with an airtight seal when applied to the horse. 
Consequently, these systems are rarely used in equine practice. 
 
Spacers and facemasks 
Currently, equine inhalation therapy (via both nebulisation and MDIs) almost invariably 
involves the use of a holding chamber or spacer, either applied directly to one nostril via a 
flexible nose piece (e.g. EquineHaler®, Kruuse, Sherburn in Elmet, UK [Figure 2], 
Aerohippus®, Trudell Medical International, London, Ontario, Canada) or used in conjunction 
with a facemask (e.g. Equine Aeromask®, Trudell Medical International, London, Ontario, 
Canada [Figure 3], Flexineb®, Nortev Ltd, Galway, Ireland [Figure 1]), thus improving the 
characteristics of the aerosol and reducing the dependency on synchronisation with the 
beginning of inspiration when an MDI is used. Spacers are fitted with a series of one-way 
valves to facilitate inspired air to flow via the chamber and exhaled air to by-pass the chamber. 
In human inhalation therapy, the benefits of a spacer also include the capture of large 
aerosolised droplets which would otherwise deposit in the oropharynx, with the resultant risks 
of opportunistic oropharyngeal infections (e.g. candidiasis) and voice hoarseness. This appears 
to be less of a consideration in equine inhalation therapy due to the obligate nasal breathing 
characteristics of the horse. Spacers designed or adapted for use in infants (e.g. BabyHALER®, 
GlaxoSmithKline Inc., Ontario, Canada [Figure 4a], Volumatic®, GlaxoSmithKline Inc., 
Ontario, Canada [Figure 4b]) have also been successfully used in equine therapy due to the 
incorporation of a flexible nose piece. Although these devices offer similar advantages as 
equine-specific spacers at a lower cost, this has to be offset against the occasional difficulty in 
establishing an effective seal over the horse’s nostril. An alternative system (Equine Aerosol 
Drug Delivery System, 3M Animal Care Products, St. Paul, MN, USA), which consisted of a 
spacer designed for drug delivery directly into the horse’s nostril, underwent preliminary 
investigation over a decade ago with some promising results in relation to comparative drug 
delivery (Derksen et al 1996); however, this device failed to reach the commercial market.  
 
The accumulation of static electricity within spacers and facemasks should be avoided as this 
has been shown to result in a significant retention of drug within the holding chamber. 
Consequently, towel drying of these devices following cleaning is contraindicated; rather they 
should be allowed to drip dry prior to subsequent use (Table 1). 
 
Available medications for equine inhalation therapy  
A wide array of medications can be delivered by the inhaled route; however, inappropriate 
delivery of drugs not evaluated for inhaled administration may result in airway inflammation 
and/or bronchospasm. Furthermore, when applying inhaled therapy using medicines not 
authorised for this route of administration, care should always be taken to ensure clinical 
justification for this approach through adherence to the cascade and due consideration should 
always be applied to any associated changes in appropriate drug withdrawal times. This review 
will focus on medications which have been reported in the literature and which are considered 
appropriate for this route of administration. Such medications fall into the following categories: 
corticosteroids, bronchodilators, cromones and antimicrobials. Table 2 lists the medications 
commonly administered by MDI in equine inhalation therapy. Recommended dosages are also 
listed; however, as previously stated, appreciation of the numerous factors which influence 
drug output (e.g. delivery device, spacer, breathing pattern) and the marked variation in drug 
delivery even under controlled experimental conditions renders any attempts to develop 
accurate dosing recommendations problematic (Table 1). This is highlighted by the marked 
variation in apparently efficacious MDI-generated beclomethasone dosages (ranging from 
500µg to 3750µg q12h) reported in the veterinary literature. The dosage guidelines provided 
are mostly derived from a number of studies which assessed clinical efficacy by a variety of 
methods (e.g. clinical scoring and pulmonary function), primarily in severe equine asthma. 
 
Corticosteroids 
In human medicine, the use of inhaled corticosteroids has been shown to be highly beneficial 
in the treatment of asthma and consequently, this therapeutic approach has been adopted for 
the treatment of equivalent conditions in the horse; namely, severe and non-infectious mild to 
moderate equine asthma. The proposed benefits of the inhalation route for corticosteroid 
administration include the local delivery of high drug concentrations at the site of 
inflammation, an advantage further supported by the large number of glucocorticoid receptors 
within the bronchial epithelium and pulmonary vascular endothelial cells. An additional benefit 
of this therapeutic approach is the theoretical minimisation of systemic adverse effects 
including laminitis and adrenal suppression. Any systemically absorbed drug is rapidly 
eliminated, thus reducing drug systemic life span. However, inhaled beclomethasone has been 
shown to decrease plasma cortisol, indicating feedback inhibition of the adrenal gland and one 
study reported no difference in serum cortisol concentrations between horses with severe 
asthma treated with aerosolized beclomethasone (1320µg q12h) and those treated with 
intravenous (0.1mg/kg q24h) dexamethasone (Rush et al 1998). Similarly, adrenal suppression 
is a recognised consequence of inhaled corticosteroid therapy in humans, predominantly, but 
not exclusively in children and in association with high dose administration, resulting in 
recommendations for adrenal suppression screening in select patient groups (Sannarangappa 
and Jalleh 2014). Beclomethasone diproprionate (Figure 5) and fluticasone proprionate are the 
most commonly used corticosteroids in equine inhalation therapy, both of which are available 
as MDIs. Others include triamcinolone acetonide and budesonide. Fluticasone is generally 
regarded as a more potent corticosteroid than beclamethasone and, compared with systemic 
(intravenous) dexamethasone, resulted in less suppression of endogenous serum cortisol. 
Furthermore, long term (11 months) administration of inhaled fluticasone resulted in no 
significant effects on measured innate and adaptive immune parameters, thus supporting its 
potential use as a maintenance therapy for severe equine asthma (Dauvillier et al 2011).  
Recently, anecdotal reports are emerging of the inhaled administration of nebulised 
dexamethasone preparations licenced for intravenous use. To the authors’ knowledge, there are 
no published studies which have critically evaluated the efficacy or safety of this approach. 
 
Bronchodilators 
Bronchodilators relax airway smooth muscle and their use in horses is most commonly applied 
to cases of severe equine asthma, where they represent a form of symptomatic therapy which 
is applied to transiently relieve lower airway obstruction while additional environmental and 
pharmacological interventions are aimed at preventing and controlling the underlying airway 
inflammation. Additionally, bronchodilators may be used prior to other forms of inhalation 
therapy to maximise drug deposition within the lower airways (Rush et al 1999) and in rare 
cases of pulmonary oedema to reduce pulmonary water content. When used to relieve airway 
obstruction in clinical cases, it should be remembered that a reduction in airway calibre may 
result from a variety of mechanisms, including bronchospasm, mucus plugging of the airways 
and peribronchiolar thickening due to cellular accumulation and smooth muscle and collagen 
hyperplasia. Therefore, incomplete resolution of lower airway obstruction following the 
administration of inhaled bronchodilators may either reflect poor drug penetration of the lower 
airways or a significant contribution of these latter factors to the overall airway narrowing. 
 
Two classes of bronchodilators exist; anticholinergics and beta-2 adrenergic agonists. As 
bronchial smooth muscle tone is largely influenced by the parasympathetic supply, 
anticholinergic drugs, competitive inhibitors of acetylcholine, have been shown to be more 
efficacious with regard to their bronchodilatory effects. Ipratropium is the principal 
anticholinergic drug used in inhalation therapy which, due to its targeted deposition and poor 
absorption from the lung, is not generally associated with the systemic adverse effects seen 
with systemically administered anticholinergics (e.g atropine), including tachycardia and 
gastrointestinal stasis. However, reported side effects in humans include thickening of 
bronchial secretions, decreased mucociliary clearance and inhibition of cilia beating. Inhaled 
ipratropium provides effective bronchodilation for 4 to 6 hours. 
 
Despite the superior bronchodilatory effects of anticholinergics, beta-2 adrenergic drugs are 
used more commonly in equine practice. This class of drug binds to the widespread beta-2 
adrenoreceptors on the surface of airway smooth muscle. These include short acting (1-2 h 
duration) drugs such as albuterol (also termed salbutamol; Figure 6) and longer acting 
salmeterol (up to 12 h duration), which has a slower onset of action (15-30 min). In addition to 
promoting bronchodilation, beta-2 adrenergic agonist drugs enhance mucociliary clearance 
from the lung and have moderate anti-inflammatory effects. As anticholinergics and beta-2 
agonists tend to exert their bronchodilatory effects at different levels throughout the airways, 
anticholinergics primarily at the larger airways and beta-2 agonists primarily in the peripheral 
airways, their combined use can have beneficial additive effects (Hoffman et al 1993). 
Preparations containing both ipratropium and albuterol are commercially available; however, 
the authors have no direct experience of using these combined preparations.  
 
Drug combinations 
The use of MDIs containing a combination of both a corticosteroid and a long acting 
bronchodilator is becoming increasingly popular in the control of human asthma, with reports 
of improved symptom control as well as greater convenience. Such “combination medications” 
(e.g. budesonide and formoterol [Symbiocort®, AstraZeneca Pharmaceuticals LP, Wilmington, 
DE, USA], fluticasone and salmeterol [Seretide®, GlaxoSmithKline Inc., Uxbridge, UK] 
beclomethasone and formoterol [Fostair®, Cheisi Ltd., Sheadle, UK; Figure 7]) have not yet 
been evaluated in the horse. However, despite the increased costs associated with this approach, 
there may be clinical advantages to this approach during the early treatment phase of certain 
cases of severe equine asthma.  
 
Antimicrobials 
By avoiding the necessity to administer larger doses of systemic antimicrobials to attain 
adequate concentrations in the respiratory secretions, inhaled antimicrobial therapy offers some 
advantages over other routes of administration, including a likely reduction in the risk of 
systemic adverse effects. Indeed, the achievement of high and prolonged drug concentrations 
within the airways whilst maintaining low serum concentrations has been clearly demonstrated 
with various antibiotics (gentamicin and marbofloxacin) when aerosolised delivery has been 
compared with systemic (intravenous) administration (McKenzie et al 2000, Art et al 2007). 
This approach has been used in humans for a number of years, particularly aimed at the 
treatment or prevention of Pseudomonas aeruginosa colonization of the airways in cystic 
fibrosis (CF), but also more recently in the treatment of non-CF bronchiectasis and ventilator-
associated pneumonia. With the exception of CF treatment, the majority of inhaled 
antimicrobial treatments applied in human medicine continue to rely on the “off label” use of 
antimicrobials designed for parenteral administration. Although the presence of preservatives 
and the non-physiological composition of many antimicrobial preparations have the potential 
to render them unsuitable for inhalation therapy, there remains a limited amount of information 
within the literature addressing this matter. Both gentamicin (50mg/ml) and cefquinome 
(45mg/ml) have been administered to horses without inducing any significant airway 
inflammation and no detrimental effects on pulmonary function were detected following 
cefquinome (45mg/ml) and marbofloxacin (25mg/ml) inhalation (Art et al 2007, Art et al 
2010). Despite these apparently encouraging results and the reported efficacy of this approach 
in equine neonatology, there is significant lack of efficacy studies in adult equine lung 
infections. One study on racehorses with lower airway inflammation did reveal comparable 
results (improvements in tracheal secretion cytology and bacteriology and rate of recurrence of 
bacteria isolation) when inhaled amikacin (3.3mg/kg) treatment was compared with systemic 
(10mg/kg) administration of the drug (Ferrucci et al 2013). It is clear that further studies are 
required before an objective consensus on the value of inhaled antimicrobials can be reached. 
However, factors other than the inflammation and bronchospasm inducing capacity of the drug 
also require particular consideration in relation to this therapeutic approach. Firstly, many of 
the conditions which may theoretically warrant the delivery of antimicrobials to the airways 
are also associated with severely compromised ventilation of the affected lung segment, either 
through consolidation, airway narrowing or the accumulation of tenacious secretions within 
the airways, factors which will significantly reduce the deposition of any inhaled medication. 
Under such circumstances, reliance on haematogenous delivery of the drug may be more 
effective. Secondly, careful compliance with appropriate antimicrobial stewardship policies 
should be ensured. This relates primarily to the appropriateness of the antimicrobial selected, 
particularly in light of the variable, yet inevitable environmental and personnel exposure to the 
aerosolised drug during administration. Such practices have the potential to expose a wide 
variety of bacteria to sub-therapeutic levels of antimicrobials with the subsequent risk of 
promoting the selection of resistant strains.  
 
Cromones 
The administration of sodium cromoglycate to horses with severe equine asthma was first 
reported over 30 years ago. The mechanism of action of this treatment is not fully understood; 
however, it has been attributed to a local effect on nerve endings, reduced leucocyte 
recruitment, and stabilisation of airway mast cells, the latter effect theoretically rending this 
approach more applicable to disease prophylaxis in the face of anticipated allergen exposure. 
Although the role of mast cells in severe equine asthma remains speculative, a sub-category of 
mild to moderate asthma is characterised by increased metachromatic cell ratios in the airways 
and the authors are aware of a renewed interest in the application of this therapeutic approach 
to this particular syndrome. Although no product is currently licensed for inhaled 
administration to horses, licenced human preparations containing cromolyn sodium have 
traditionally been used for equine inhalation therapy, initially via nebulisation of 2% solution 
and more recently via commercially available MDIs, currently available in the UK (Intal CFC-
free Inhaler®). Although nedocromil sodium (Tilade®) has been used as an alternative to 
cromolyn sodium in the treatment of human asthma and has been proposed as a treatment for 
equine metachromatic mild to moderate equine asthma, there is currently no published data on 
its efficacy in the horse.  
 
Miscellaneous treatments 
In addition to its diuretic effects, frusemide, when administered by inhalation, has been shown 
to have bronchodilatory effects via incompletely understood and likely complex mechanisms 
(Broadstone et al 1991). Consequently, this approach has shown some efficacy in the treatment 
of severe equine asthma. As the process of mucus clearance from the airways is dependent on 
a number of factors, including mucus viscosity, mucus volume and ciliary activity, each of 
these have been targeted as a means of improving the efficiency of this process. With regard to 
inhalation therapy, the most commonly used approach is to administer aerosolised saline in an 
attempt to decrease the viscosity of the mucus, thus enhancing its clearance. The efficacy of 
such approaches remains unclear.  
 
Summary 
Inhalation therapy is now commonly used in the treatment of a variety of equine respiratory 
conditions with a wide variety of drugs being routinely administered via this route. Despite the 
many advantages associated with this therapeutic approach, there are a number of 
considerations which have to be applied to each case in order to determine whether this route 
of drug administration is applicable. Such considerations include the intended target site for 
drug deposition, the capability of the available inhalation delivery systems to generate aerosols 
with a particle size distribution pattern capable of reaching the target site, any physiological, 
pharmacological or pathological factors which may compromise ventilation of the target site, 
any potential detrimental effects of direct drug delivery to the airways or handler exposure to 
drug aerosols, the costs associated with the drug and/or required delivery equipment, the time 
constraints and commitment of the owner and the duration of anticipated treatment. Only when 
these considerations are made on a case-by-case basis can an opinion be reached with regard 
to the suitability of this approach, which, if deemed suitable, continues to offer a valuable 
means of treating airway disease in the horse. 
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Figure	legends	
	Figure	1:	Image	depicting	ultrasonic	nebulisation	of	solubilised	drug	to	a	horse	using	the	Flexineb®	
system	(Nortev	Ltd,	Galway,	Ireland).	The	aerosol	is	created	by	vibrations	of	a	piezo-electric	crystal	
driven	by	a	battery-generated	alternating	electric	field.	The	mounting	of	the	aerosol	holding	
chamber	and	the	battery	on	the	mask	facilitates	the	administration	of	inhaled	therapy	without	the	
necessity	for	continuous	head	restraint	or	close	proximity	to	a	mains	power	supply.	
	Figure	2:	The	EquineHaler®	(Kruuse,	Sherburn	in	Elmet,	UK)	spacer	device,	specifically	designed	for	
MDI-generated	drug	administration	to	the	horse.	
	
	Figure	3:	Administration	of	MDI-generated	inhaled	medication	to	a	horse	using	the	Equine	
Aeromask®	system	(Trudell	Medical	International,	London,	Ontario,	Canada),	with	associated	holding	
chamber	(spacer).	
	
		
Figure	4:	Alternatives	to	equine-specific	spacers	include	(a)	the	Babyhaler®	and	(b)	the	Volumatic®	
spacer	(both	GlaxoSmithKline	Inc.,	Ontario,	Canada).	Although	their	adaptation	for	use	in	infants	
includes	the	incorporation	of	a	flexible	nose	piece,	compared	with	the	equine-specific	spacers,	it	can	
be	more	difficult	to	establish	an	appropriate	seal	at	the	nostril.	
	 	
	Figure	5:	Beclomethasone	diproprionate	MDI	(Clenil	modulite®,	Cheisi	Ltd.,	Sheadle,	UK),	a	
commonly	used	product	for	inhaled	steroid	medication	in	the	horse.	
Figure	6:	Salbutamol	MDI,	a	commonly	used	beta-2	adrenergic	agonist	bronchodilator	with	a	rapid	
onset	but	limited	duration	(1-2h)	of	action.		
Figure	7:	Example	of	an	MDI	product	(Fostair®,	Cheisi	Ltd.,	Sheadle,	UK)	containing	both	a	
corticosteroid	(beclomethasone)	and	long-acting	bronchodilator	(formoterol).	Other	
corticosteroid/bronchodilator	combinations	are	available.	The	use	of	such	“combination	
medications”	is	becoming	increasingly	popular	in	the	control	of	human	asthma;	however,	they	have	
not	yet	been	objectively	evaluated	in	the	horse.	
	
	  
Table	1:	A	list	of	factors	which	will	influence	the	efficiency	of	drug	delivery	to	the	lower	airways.	
Factor	 Mechanism	of	influence	
Properties	of	drug	solution	(jet	and	ultrasonic	
nebulisers)	
• Viscosity,	density,	surface	tension	and	hygroscopic	growth	
potential	of	the	solution	will	influence	aerosolised	particle	
diameter	
Method	of	aerosolisation	 • Jet	and	ultrasonic	nebulisers	generate	aerosols	with	more	
variation	in	particle	size	distribution	compared	with	MDIs	
Appropriate	use	of	device		
-	Flow	rates	(jet	nebulisers)		
• When	using	jet	nebulisers,	particle	size	is	inversely	proportional	
to	air	flow	rates	used	to	generate	the	aerosol		
Appropriate	use	of	device		
-	Shaking	device	prior	to	actuation	(MDI)	
• Shaking	MDIs	prior	to	use	to	ensures	appropriate	mixing	of	
drug	and	propellant	
Appropriate	use	of	device		
-	Counting	total	number	of	actuations	(MDI)	
• MDIs	will	continue	to	express	propellant	upon	actuation	even	
following	depletion	of	the	active	drug	
Appropriate	use	of	device		
-	Coordinating	actuation	with	respiratory	cycle	
(MDI)	
• Beneficial	to	actuate	the	MDI	into	spacer	during	a	period	of	
zero,	immediately	prior	to	inhalation	
Appropriate	maintenance	of	equipment	
-	Cleaning	(ultrasonic	nebulisers)	
• Failure	to	adhere	to	manufacturer’s	instructions	may	influence	
the	efficiency	of	aerosol	generation	
Appropriate	maintenance	of	equipment	
-	Extended	and	repeated	use	of	disposable	
nebuliser	cups	(jet	nebulisers)	
• Re-use	of	disposable	nebuliser	cups,	not	intended	for	extended	
use,	will	reduce	the	respirable	particle	fraction	of	the	aerosol	
Appropriate	maintenance	of	equipment	
-	Drying	of	spacers	and	facemasks	
• Towel	drying	of	facemasks	and	spacers	has	the	potential	to	
result	in	sufficient	static	electricity	accumulation	to	significantly	
attract	aerosolised	particles,	thus	preventing	their	passage	into	
the	airway.	Drip	drying	of	this	equipment	is	advisable.	
Efficiency	of	lung	ventilation	 • Various	physiological	or	pathological	factors	will	influence	
ventilation	of	different	lung	segments.	Examples	include	drug-	
or	disease-associated	bronchospasm,	lung	
consolidation/atalectesis,	mucus	plugging	
Breathing	strategy	of	horse	 • Any	deviation	from	a	perceived	optimal	breathing	pattern	
(slow	inhalation	followed	by	a	period	of	zero	flow)	will	impact	
on	the	efficiency	of	delivery.	Examples	include	short	rapid	
respirations	and	prolonged	periods	of	breath	holding	
Random	variation	in	drug	output	from	device	
(nebulisers	and	MDIs)	
• There	is	marked	variation	in	drug	output	from	MDIs	(between	
actuations)	and	nebulisers	(between	treatment	periods),	which	
appear	to	be	independent	of	the	above	factors.	
	
	
	
	 	
Table	2:	A	selection	of	drugs	available	as	MDIs	commonly	used	in	equine	inhalation	therapy.	These	
products	are	all	unlicensed	for	use	 in	 the	horse	and	the	dosing	regimens	provided	are	suggestions	
only.	Consideration	should	be	given	to	the	various	factors	which	may	influence	drug	delivery	to	the	
lower	airways	and	the	variation	in	drug	output	from	the	devices	(see	Table	1).	
Drug	class	/	active	
component	
Tradename	
examples	
Dose	 Dose	per	
actuation	
Actuations	per	
500kg	horse	
Frequency	
Corticosteroids	 	 	 	 	 	
Beclomethasone	
dipropionate	
Clenil	modulite®	 1	to	5	µg/kg	 250	µg	 2	to	10	 q	12h	
Fluticasone	propionate	 Flixotide®	 2	to	4		µg/kg	 250	µg	 4	to	8	 q	12h	
Anticholinergics	 	 	 	 	 	
Ipratropium	bromide	 Atrovent®	 0.4	to	0.8 µg/kg	 40	µg	 5	to	10	 q	4	to	6h	
Beta-2	adrenergic	agonists	 	 	 	 	 	
Salbutamol	 Ventolin®	 2	µg/kg	 100	µg	 10	 q	2	to	4h	
Salmeterol	 Serevent®	 0.5	µg/kg	 25	µg	 10	 q	12h	
Combination	drugs	 	 	 	 	 	
Salmeterol	and	
fluticasone	
Seretide®	 0.2	to	0.4		µg/kg	*	
2	to	4		µg/kg	*	
25	µg	*	
250	µg	*	
4	to	8	*	 q	12h	
Formoterol	and	
beclomethasone		
Fostair®	 0.06	to	0.18	µg/kg	*	
1	to	3		µg/kg	*	
6	µg	*	
100	µg	*	
5	to	15	*	 q	12h	
Chromones	 	 	 	 	 	
Sodium	cromoglicate	 Intal	CFC-free®	 0.04	to	0.06	mg/kg	*	 5	mg	 4	to	6	*	 q	6-12h	
*	 Calculated	 doses	 extrapolated	 from	 a	 combination	 of	 anecdotal	 evidence	 of	 efficacy,	 equivalent	 human	 dosing	 regimens	 and	
recommended	doses	of	individual	components	in	horses	(combination	therapy).		
	
	
 
